卵巢癌临床试验导航 | 海外癌症临床试验导航

正在招募 Phase 3

NCI NCT06915025 / NCI-2025-04630

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

AI 简述这是一项III期试验，研究IMNN-001联合化疗用于新诊断的晚期卵巢癌。

?

适用疾病: Stage IIIC Ovarian Cancer；Stage IV Ovarian Cancer；Stage IIIB Fallopian Tube Cancer
干预: 未列出
地点: United States
申办方: Imunon

正在招募 Phase 3 药物其他

ClinicalTrials.gov NCT04111978

MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)

AI 简述这是一项III期试验，比较来曲唑与安慰剂用于上皮性卵巢癌维持治疗。

?

适用疾病: Ovarian Neoplasm Epithelial；Fallopian Tube Neoplasms；Peritoneal Neoplasms
干预: Letrozole 2.5mg，Placebo
地点: Austria，Germany，Switzerland
申办方: Swiss GO Trial Group

正在招募 Phase 3 生物制剂药物

ClinicalTrials.gov / NCI NCT05281471 / NCI-2023-04441

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

AI 简述这是一项III期试验，比较Olvi-Vec联合铂类双药+贝伐珠单抗与化疗+贝伐珠单抗用于铂耐药/难治性卵巢癌，在美国开展。

?

适用疾病: Platinum-resistant Ovarian Cancer；Platinum-refractory Ovarian Cancer；Fallopian Tube Cancer
干预: olvimulogene nanivacirepvec，Platinum chemotherapy: carboplatin (preferred) or cisplatin，Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin，Bevacizumab (or biosimilar)
地点: United States
申办方: Genelux Corporation

正在招募 Phase 3 药物其他

ClinicalTrials.gov / NCI NCT05659381 / NCI-2023-08813

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

AI 简述这是一项III期试验，研究腹腔热灌注化疗后使用Niraparib用于卵巢癌、原发性腹膜癌和输卵管癌。

?

适用疾病: Stage III Ovarian Cancer；Stage IV Ovarian Cancer；Stage III Primary Peritoneal Cancer
干预: Cisplatin，No treatment
地点: United States
申办方: GOG Foundation

正在招募 Phase 3 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06580314 / NCI-2024-04335

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

AI 简述这是一项III期试验，比较奥拉帕利联合或不联合贝伐珠单抗用于卵巢癌。

?

适用疾病: Fallopian Tube Endometrioid Adenocarcinoma；Fallopian Tube High Grade Serous Adenocarcinoma；FIGO Stage III Ovarian Cancer 2014
干预: Bevacizumab，Biospecimen Collection，Computed Tomography，Magnetic Resonance Imaging
地点: United States，Japan，Puerto Rico
申办方: NRG Oncology

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT07214779 / NCI-2026-02919

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

AI 简述这是一项3期试验，比较INCB123667与医生选择化疗用于铂耐药卵巢癌伴CCNE1过表达。

?

适用疾病: Ovarian Cancer；Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma；Platinum-Resistant Fallopian Tube High Grade Serous Adenocarcinoma
干预: INCB123667，Investigator's choice of chemotherapy
地点: United States，Australia，Belgium，Canada 等 11 个
申办方: Incyte Corporation

正在招募 Phase 3 药物

ClinicalTrials.gov NCT07286266

A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

AI 简述这是一项III期试验，比较Mocertatug rezetecan与标准化疗用于铂耐药卵巢癌，在澳大利亚、加拿大、日本等地开展。

?

适用疾病: Ovarian Neoplasms
干预: Mocertatug rezetecan，Paclitaxel，Pegylated liposomal doxorubicin (PLD)，Topotecan
地点: Australia，Canada，Japan
申办方: GlaxoSmithKline

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT07318558 / NCI-2026-02084

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

AI 简述这是一项III期试验，研究Sacituzumab tirumotecan用于非HRD阳性晚期卵巢癌，在美国、阿根廷等地开展。

?

适用疾病: Ovarian Neoplasms；Ovarian Cancer；Stage III Ovarian Cancer
干预: Sacituzumab tirumotecan，Bevacizumab，Rescue Medications
地点: United States，Argentina，Australia，Austria 等 22 个
申办方: Merck Sharp & Dohme LLC

正在招募 Phase 3 药物

ClinicalTrials.gov NCT07546500

A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

AI 简述这是一项III期试验，比较Azenosertib与研究者选择化疗用于铂耐药高级别浆液性卵巢癌（Cyclin E1阳性），在美国、澳大利亚、比利时、加拿大等地开展。

?

适用疾病: Ovarian Cancer
干预: Investigator's choice of Chemotherapy，Azenosertib
地点: United States，Australia，Belgium，Canada 等 8 个
申办方: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

正在招募 Phase 1, Phase 2

NCI NCT03564340 / NCI-2018-01362

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

AI 简述这是一项I/II期试验，研究REGN4018单药或联合Cemiplimab用于复发性卵巢癌或其他MUC16+癌症。

?

适用疾病: Stage III Ovarian Cancer；Stage IV Ovarian Cancer；Stage III Fallopian Tube Cancer
干预: 未列出
地点: United States
申办方: Regeneron Pharmaceuticals, Inc.

正在招募 Phase 2

NCI NCT03878849 / NCI-2019-02288

Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer

AI 简述这是一项II期试验，研究2X-121用于复发性晚期卵巢癌、输卵管癌或原发性腹膜癌。

?

适用疾病: Recurrent Fallopian Tube Cancer；Recurrent Primary Peritoneal Cancer；Stage III Ovarian Cancer
干预: 未列出
地点: United States
申办方: Allarity Therapeutics

正在招募 Phase 2

NCI NCT04055649 / NCI-2019-05252

ONC201 and Paclitaxel in Treating Patients with Platinum-Resistant Refractory or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

AI 简述这是一项II期试验，研究ONC201联合紫杉醇用于铂类耐药或难治性卵巢癌、输卵管癌或原发性腹膜癌。

?

适用疾病: Recurrent Fallopian Tube Cancer；Recurrent Primary Peritoneal Cancer；Platinum-Resistant Ovarian Cancer
干预: 未列出
地点: United States
申办方: Wayne State University/Karmanos Cancer Institute

正在招募 Phase 2

NCI NCT04449549 / NCI-2020-04956

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

AI 简述这是一项II期试验，研究尼罗替尼和紫杉醇用于罕见肿瘤，在美国开展。

?

适用疾病: Lepidic Adenocarcinoma；Malignant Solid Tumor；Stage IV Anal Cancer
干预: 未列出
地点: United States
申办方: National Cancer Institute

正在招募 Phase 1, Phase 2

NCI NCT04300556 / NCI-2020-06147

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

AI 简述这是一项I/II期试验，研究MORAb-202用于多种实体瘤，包括卵巢癌和肺癌。

?

适用疾病: High Grade Ovarian Serous Adenocarcinoma；Primary Peritoneal High Grade Serous Adenocarcinoma；High Grade Fallopian Tube Serous Adenocarcinoma
干预: 未列出
地点: United States
申办方: Eisai Inc

正在招募 Phase 1, Phase 2

NCI NCT04657068 / NCI-2021-04129

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究ART0380联合吉西他滨或伊立替康用于晚期或转移性实体瘤。

?

适用疾病: High Grade Ovarian Serous Adenocarcinoma；Primary Peritoneal High Grade Serous Adenocarcinoma；High Grade Fallopian Tube Serous Adenocarcinoma
干预: 未列出
地点: United States
申办方: Artios Pharma Ltd

正在招募 Phase 1, Phase 2

NCI NCT04787042 / NCI-2021-09248

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

AI 简述这是一项I/II期试验，研究ST-067用于实体瘤、黑色素瘤、肾细胞癌和三阴性乳腺癌，在美国开展。

?

适用疾病: Recurrent Merkel Cell Cancer；Metastatic Urothelial Cancer；Recurrent Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Simcha IL-18, Inc.

正在招募 Phase 2

NCI NCT05231122 / NCI-2021-13609

Pembrolizumab Combined with Bevacizumab with or without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients with Recurrent Ovarian Cancer

AI 简述这是一项II期试验，研究Pembrolizumab联合贝伐珠单抗加或不加CDX-1140用于复发性卵巢癌。

?

适用疾病: Recurrent Fallopian Tube Cancer；Recurrent Primary Peritoneal Cancer；Recurrent Ovarian Endometrioid Adenocarcinoma
干预: 未列出
地点: United States
申办方: Roswell Park Cancer Institute

正在招募 Phase 1, Phase 2

NCI NCT05417594 / NCI-2022-05317

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

AI 简述这是一项1/2期试验，研究AZD9574单药或联合其他抗癌药用于晚期实体瘤，在美国开展。

?

适用疾病: Recurrent Fallopian Tube Cancer；Recurrent Primary Peritoneal Cancer；Castration-Resistant Prostate Cancer
干预: 未列出
地点: United States
申办方: AstraZeneca Pharmaceuticals LP

正在招募 Phase 2

NCI NCT05453825 / NCI-2022-07031

A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors

AI 简述这是一项II期试验，研究Navicixizumab单药或联合用于晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: OncXerna Theraputics, Inc.

正在招募 Phase 1, Phase 2

NCI NCT05592626 / NCI-2023-00103

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究STAR0602用于多种晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Castration-Resistant Prostate Cancer
干预: 未列出
地点: United States
申办方: Marengo Therapeutics, Inc.

正在招募 Phase 1, Phase 2

NCI NCT05200559 / NCI-2023-00563

E7777 and Pembrolizumab for the Treatment of Patients with Recurrent or Metastatic Cancer

AI 简述这是一项I/II期试验，研究E7777联合帕博利珠单抗用于复发或转移性实体瘤。在美国开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: University of Pittsburgh Cancer Institute (UPCI)

正在招募 Phase 1, Phase 2

NCI NCT05739981 / NCI-2023-01824

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

AI 简述这是一项I/II期试验，在美国研究IMNN-001联合BEV和NACT用于新诊断晚期卵巢癌、输卵管癌或原发性腹膜癌。

?

适用疾病: High Grade Ovarian Serous Adenocarcinoma；Primary Peritoneal High Grade Serous Adenocarcinoma；High Grade Fallopian Tube Serous Adenocarcinoma
干预: 未列出
地点: United States
申办方: Imunon

正在招募 Phase 2

NCI NCT05467670 / NCI-2023-03170

ALX148 in Combination with Liposomal Doxorubicin and Pembrolizumab for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

AI 简述这是一项II期试验，在美国开展，研究ALX148联合脂质体多柔比星和帕博利珠单抗用于复发铂耐药卵巢癌。

?

适用疾病: Platinum-Resistant Ovarian Cancer；Recurrent Ovarian Endometrioid Adenocarcinoma；Recurrent Ovarian Clear Cell Adenocarcinoma
干预: 未列出
地点: United States
申办方: University of Pittsburgh Cancer Institute (UPCI)

正在招募 Phase 1, Phase 2

NCI NCT05735080 / NCI-2023-04176

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

AI 简述这是一项1/2期试验，研究INX-315用于晚期乳腺癌和卵巢癌等，在美国和澳大利亚开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Breast Cancer
干预: 未列出
地点: United States
申办方: Incyclix Bio

正在招募 Phase 2

NCI NCT05887609 / NCI-2023-04331

Mirvetuximab Soravtansine and Olaparib for the Treatment of Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube Cancer with Positive Folate Receptor-Alpha Expression

AI 简述这是一项II期试验，研究Mirvetuximab Soravtansine和奥拉帕利用于复发铂敏感卵巢癌、腹膜癌及输卵管癌。

?

适用疾病: Recurrent Ovarian Endometrioid Adenocarcinoma；Recurrent High Grade Ovarian Serous Adenocarcinoma；Recurrent Platinum-Sensitive Ovarian Carcinoma
干预: 未列出
地点: United States
申办方: UCHealth University of Colorado Hospital

正在招募 Phase 1, Phase 2

NCI NCT05684965 / NCI-2023-06173

XTX301 in Patients With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究XTX301用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Xilio Development, Inc.

正在招募 Phase 1, Phase 2

NCI NCT05867251 / NCI-2023-06475

Study of AVZO-021 in Patients With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究AVZO-021单药或联合用药用于晚期实体瘤。

?

适用疾病: Stage III Breast Cancer；Stage IV Breast Cancer；Stage III Uterine (including Endometrial) Cancer
干预: 未列出
地点: United States
申办方: Avenzo Therapeutics, Inc.

正在招募 Phase 2

NCI NCT06083844 / NCI-2023-08686

Pembrolizumab in Combination with Bevacizumab and Cyclophosphamide for the Treatment of High Grade Ovarian Cancer with Documented Minimal Residual Disease after Frontline Treatment

AI 简述这是一项II期试验，研究Pembrolizumab联合贝伐珠单抗、环磷酰胺用于高级别卵巢癌一线治疗后微小残留病变，在美国开展。

?

适用疾病: Ovarian Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT05000294 / NCI-2023-08761

Tivozanib and Atezolizumab for the Treatment of Advanced, Unresectable, or Metastatic Immunologically Cold Tumor Types

AI 简述这是一项I/II期试验，研究阿特珠单抗联合Tivozanib用于免疫冷肿瘤类型，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；FIGO Stage IVA Ovarian Cancer；FIGO Stage IVB Ovarian Cancer
干预: 未列出
地点: United States
申办方: UF Health Cancer Institute - Gainesville

正在招募 Phase 1, Phase 2

NCI NCT04752826 / NCI-2023-10441

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

AI 简述这是一项1/2期试验，研究BI-1808单药或联合帕博利珠单抗用于晚期恶性肿瘤，包括卵巢癌、T细胞淋巴瘤等。

?

适用疾病: Recurrent Fallopian Tube Cancer；Recurrent Primary Peritoneal Cancer；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: BioInvent International AB

正在招募 Phase 1, Phase 2

NCI NCT05914116 / NCI-2024-01206

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

AI 简述这是一项I/IIa期试验，在美国研究DB-1311/BNT324用于晚期/转移性实体瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: DualityBio Inc.

正在招募 Phase 1, Phase 2

NCI NCT06425926 / NCI-2024-05762

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

AI 简述这是一项I/II期试验，在美国研究GIM-531单独或联合抗PD-1抗体用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Stage III Lung Cancer
干预: 未列出
地点: United States
申办方: Georgiamune Inc

正在招募 Phase 2

NCI NCT06365853 / NCI-2024-05878

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

AI 简述这是一项II期试验，评估Mirvetuximab Soravtansine治疗期间的眼毒性用于复发卵巢癌，在美国开展。

?

适用疾病: Recurrent Platinum-Resistant Ovarian Carcinoma；Recurrent Platinum-Sensitive Ovarian Carcinoma；Fallopian Tube Cancer
干预: 未列出
地点: United States
申办方: Abbvie

正在招募 Phase 2

NCI NCT05145569 / NCI-2024-05942

Chemotherapy with or without HCW9218 before Surgery for the Treatment of Stage III-IV High Grade Serous Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

AI 简述这是一项II期试验，研究化疗联合或不联合HCW9218用于III-IV期高级别浆液性卵巢癌、输卵管癌和原发性腹膜癌。

?

适用疾病: Stage III Ovarian Cancer；Stage IV Ovarian Cancer；Stage III Fallopian Tube Cancer
干预: 未列出
地点: United States
申办方: University of Pittsburgh Cancer Institute (UPCI)

正在招募 Phase 1, Phase 2

NCI NCT06526819 / NCI-2024-06528

SMP-3124LP in Adults With Advanced Solid Tumors

AI 简述这是一项I/II期试验，在美国开展，研究SMP-3124LP用于晚期实体瘤。

?

适用疾病: Recurrent Endometrial Serous Adenocarcinoma；Stage III Head and Neck Squamous Cell Cancer；Stage IV Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Sumitomo Pharma America, Inc.

正在招募 Phase 1, Phase 2

NCI NCT06090266 / NCI-2024-10204

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

AI 简述这是一项I/II期试验，研究OR502单药及联合抗癌药用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: OncoResponse, Inc.

正在招募 Phase 2

NCI NCT06330064 / NCI-2025-00431

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

AI 简述这是一项II期试验，研究Ifinatamab deruxtecan用于复发或转移性实体瘤，在美国开展。

?

适用疾病: Recurrent Bladder Urothelial Cancer；Metastatic Malignant Solid Tumor；Recurrent Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)
干预: 未列出
地点: United States
申办方: Daiichi Sankyo

正在招募 Phase 4

NCI NCT06412120 / NCI-2025-02553

Niraparib for Maintenance Treatment in Women of African Ancestry with Stage III-IV Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer after Front-line Treatment

AI 简述这是一项IV期试验，研究Niraparib维持治疗用于非洲裔女性III-IV期卵巢癌、输卵管癌或腹膜癌，在美国和尼日利亚开展。

?

适用疾病: High Grade Ovarian Serous Adenocarcinoma；Primary Peritoneal High Grade Serous Adenocarcinoma；High Grade Fallopian Tube Serous Adenocarcinoma
干预: 未列出
地点: United States，Nigeria
申办方: University of Miami Miller School of Medicine-Sylvester Cancer Center

正在招募 Phase 2

NCI NCT05952453 / NCI-2025-02751

Carboplatin, Paclitaxel, and Pembrolizumab Before Surgery Followed by Olaparib and Pembrolizumab with or without Bevacizumab for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Primary Peritoneal Cancer

AI 简述这是一项II期试验，研究Carboplatin、Paclitaxel和Pembrolizumab用于III-IV期卵巢癌、输卵管癌或原发性腹膜癌。

?

适用疾病: High Grade Ovarian Serous Adenocarcinoma；Invasive Ovarian Micropapillary Serous Carcinoma；FIGO Stage III Ovarian Cancer
干预: 未列出
地点: United States
申办方: University of Alabama at Birmingham Cancer Center

正在招募 Phase 2

NCI NCT06890338 / NCI-2025-04095

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

AI 简述这是一项II期试验，研究卡铂联合Mirvetuximab Soravtansine用于FRα表达的晚期浆液性卵巢癌等，在美国开展。

?

适用疾病: FIGO Stage III Ovarian Cancer；Stage III Fallopian Tube Cancer；Stage IV Fallopian Tube Cancer
干预: 未列出
地点: United States
申办方: Abbvie

正在招募 Phase 2

NCI NCT06953089 / NCI-2025-05085

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

AI 简述这是一项II期试验，研究DB-1311联合BNT327或DB-1305用于晚期转移性实体瘤，在美国开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: DualityBio Inc.

正在招募 Phase 1, Phase 2

NCI NCT06907043 / NCI-2025-06439

A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

AI 简述这是一项I/II期试验，研究PARP1抑制剂EIK1004用于晚期实体瘤。

?

适用疾病: Recurrent Fallopian Tube Cancer；Recurrent Primary Peritoneal Cancer；Recurrent Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Eikon Therapeutics

正在招募 Phase 1, Phase 2

NCI NCT07124117 / NCI-2025-07305

A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，在美国研究OBI-902用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: OBI Pharma, Inc

正在招募 Phase 2

NCI NCT07059845 / NCI-2025-07538

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

AI 简述这是一项II期试验，研究多种药物组合静脉注射Mirvetuximab Soravtansine用于III/IV期卵巢癌、输卵管癌或原发性腹膜癌。

?

适用疾病: Stage III Ovarian Cancer；Stage IV Ovarian Cancer；Stage III Fallopian Tube Cancer
干预: 未列出
地点: United States
申办方: Abbvie

正在招募 Phase 2

NCI NCT06979596 / NCI-2025-08586

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

AI 简述这是一项II期试验，研究MK-5684用于高级别浆液性卵巢癌、腹膜癌、输卵管癌及III-IV期乳腺癌。

?

适用疾病: High Grade Ovarian Serous Adenocarcinoma；Primary Peritoneal High Grade Serous Adenocarcinoma；High Grade Fallopian Tube Serous Adenocarcinoma
干预: 未列出
地点: United States
申办方: Merck Sharp and Dohme LLC

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT04503265

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

AI 简述这是一项I/II期试验，研究AMXI-5001用于晚期实体瘤。在美国开展。

?

适用疾病: Advanced Malignant Neoplasm；Breast Cancer；Ovarian Cancer
干预: AMXI-5001:Dose Escalation Phase I，AMXI-5001:Dose Expansion Phase II
地点: United States
申办方: AtlasMedx, Incorporated

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT04550494 / NCI-2020-06906

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

AI 简述这是一项II期试验，研究Talazoparib用于携带DNA修复变异的晚期癌症患者。

?

适用疾病: Anatomic Stage III Breast Cancer AJCC v8；Anatomic Stage IV Breast Cancer AJCC v8；Castration-Resistant Prostate Carcinoma
干预: Biopsy Procedure，Biospecimen Collection，Computed Tomography，Magnetic Resonance Imaging
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04787289

A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer

AI 简述这是一项II期试验，在加拿大比较两种标准剂量Bevacizumab联合化疗用于铂耐药卵巢癌。

?

适用疾病: Ovarian Cancer；Platinum-resistant Ovarian Cancer
干预: Bevacizumab
地点: Canada
申办方: British Columbia Cancer Agency

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04918186 / NCI-2023-04857

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

AI 简述这是一项II期试验，在复发难治性高级别浆液性卵巢癌中测试多种免疫治疗方案，在美国、加拿大开展。

?

适用疾病: Ovarian Cancer；Platinum-Resistant Ovarian Cancer；Platinum-Resistant Fallopian Tube Cancer
干预: Durvalumab，BA3011，BA3021，ENB003
地点: United States，Canada
申办方: Canadian Cancer Trials Group

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05080556

Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer

AI 简述这是一项II期试验，研究卡铂适应性化疗用于铂敏感复发性卵巢癌。

?

适用疾病: Ovarian Cancer；Relapsed Ovarian Cancer；Fallopian Tube Cancer
干预: Carboplatin
地点: United Kingdom
申办方: University College, London

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05128825 / NCI-2022-03875

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

AI 简述这是一项II期试验，研究Azenosertib用于铂耐药的高级别浆液性卵巢癌等，在美国、澳大利亚等地开展。

?

适用疾病: High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer；High Grade Ovarian Serous Adenocarcinoma；Platinum-Resistant Fallopian Tube Cancer
干预: azenosertib
地点: United States，Australia，Belgium，France 等 4 个
申办方: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05183984

Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer

AI 简述这是一项II期试验，研究Niraparib联合贝伐珠单抗用于完全减灭术后的卵巢癌患者，在法国、意大利、日本、新加坡等地开展。

?

适用疾病: Ovarian Cancer
干预: Chemotherapy，Bevacizumab-Awwb，Niraparib
地点: France，Italy，Japan，Singapore 等 2 个
申办方: ARCAGY/ GINECO GROUP

正在招募 Phase 1, Phase 2 生物制剂器械

ClinicalTrials.gov NCT05329532

Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer

AI 简述这是一项1/2期试验，研究Modi-1 Moditope联合帕博利珠单抗用于乳腺癌、头颈癌、卵巢癌或肾癌，在英国开展。

?

适用疾病: Triple Negative Breast Cancer；Renal Cell Cancer；High Grade Ovarian Serous Adenocarcinoma
干预: Modi-1 Moditope，Pembrolizumab，MicronJet600™ microneedle device (NanoPass)
地点: United Kingdom
申办方: Scancell Ltd

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov NCT05465941

PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

AI 简述这是一项II期试验，研究PLX038用于转移性铂耐药卵巢癌、原发性腹膜癌和输卵管癌。

?

适用疾病: Platinum-Resistant Fallopian Tube Carcinoma；Platinum-Resistant Ovarian Carcinoma；Platinum-Resistant Primary Peritoneal Carcinoma
干预: Biopsy，Pegylated SN-38 Conjugate PLX038，Computed Tomography，Biospecimen Collection
地点: United States
申办方: Mayo Clinic

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05512208

A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib

AI 简述这是一项II期试验，研究Avutometinib联合Defactinib用于子宫内膜样癌、卵巢癌等实体瘤，在美国开展。

?

适用疾病: Endometrioid Cancer；Mucinous Ovarian Cancer；High Grade Serous Ovarian Cancer
干预: Avutometinib (VS-6766) + defactinib
地点: United States
申办方: University of Oklahoma

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05538091 / NCI-2023-03173

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

AI 简述这是一项II期试验，研究Vismodegib联合Atezolizumab用于铂耐药卵巢癌、输卵管癌或原发性腹膜癌。

?

适用疾病: Platinum-Resistant Fallopian Tube Carcinoma；Platinum-Resistant Primary Peritoneal Carcinoma；PARP Inhibitor
干预: Vismodegib，Atezolizumab
地点: United States
申办方: Ronald Buckanovich

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05824975

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

AI 简述这是一项I/II期试验，研究GI-102单药或联合其他药物用于晚期实体瘤。在美国、韩国等地开展。

?

适用疾病: Advanced Solid Tumor；Metastatic Solid Tumor；Soft Tissue Sarcoma (STS)
干预: GI-102 subcutaneous (SC)，GI-102，doxorubicin，paclitaxel
地点: United States，South Korea
申办方: GI Innovation, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05902988 / NCI-2023-08591

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

AI 简述这是一项I/II期试验，研究VLS-1488用于晚期实体瘤，包括卵巢癌、肺癌、乳腺癌等，在美国开展。

?

适用疾病: Advanced Solid Tumor；High Grade Serous Adenocarcinoma of Ovary；Squamous Non-small-cell Lung Cancer
干预: VLS-1488
地点: United States
申办方: Volastra Therapeutics, Inc.

正在招募 Phase 1, Phase 2 生物制剂手术/操作

ClinicalTrials.gov / NCI NCT05920798 / NCI-2023-03999

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

AI 简述这是一项I/II期试验，在美国研究疫苗联合Pembrolizumab治疗晚期卵巢癌、输卵管癌或原发性腹膜癌。

?

适用疾病: Fallopian Tube Carcinosarcoma；Primary Peritoneal Carcinosarcoma；Recurrent Fallopian Tube Carcinoma
干预: Biopsy，Biospecimen Collection，Computed Tomography，Magnetic Resonance Imaging
地点: United States
申办方: Mayo Clinic

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05961124

Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer

AI 简述这是一项II期试验，研究Niraparib的不同给药方案用于卵巢癌一线维持治疗，在加拿大开展。

?

适用疾病: Ovarian Cancer；Stage III Ovarian Cancer；Stage IV Ovarian Cancer
干预: Niraparib
地点: Canada
申办方: Sunnybrook Health Sciences Centre

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05983276

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

AI 简述这是一项II期试验，研究地西他滨和Selinexor联合标准化疗逆转卵巢癌耐药，在美国开展。

?

适用疾病: Ovarian Cancer
干预: Decitabine，Carboplatin，Paclitaxel，Selinexor
地点: United States
申办方: Loyola University

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05985655 / NCI-2026-01491

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究GTAEXS617用于多种晚期实体瘤。

?

适用疾病: Head and Neck Squamous Cell Carcinoma (HNSCC)；Pancreatic Adenocarcinoma；Non-small Cell Lung Cancer (NSCLC)
干预: GTAEXS617，SoC
地点: United States，Belgium，United Kingdom
申办方: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT05998135 / NCI-2023-03479

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

AI 简述这是一项II期试验，研究Atovaquone用于铂耐药卵巢癌，在美国开展。

?

适用疾病: Ovarian High Grade Serous Adenocarcinoma；Platinum-Resistant Ovarian Carcinoma；High Grade Ovarian Serous Adenocarcinoma
干预: Atovaquone，Biopsy，Computed Tomography，Paracentesis
地点: United States
申办方: Emory University

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06188520

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，在美国、澳大利亚、韩国、西班牙等地开展，研究AZD8421单药或联合用于ER+ HER2-晚期乳腺癌或高级别浆液性卵巢癌。

?

适用疾病: ER+ HER2- Advanced Breast Cancer；High-grade Serous Ovarian Cancer (HGSOC)
干预: AZD8421，Camizestrant，Ribociclib，Palbociclib
地点: United States，Australia，South Korea，Spain 等 1 个
申办方: AstraZeneca

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06303505 / NCI-2024-07935

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

AI 简述这是一项I/II期试验，研究NaPi2b ADC TUB-040用于铂耐药卵巢癌或复发难治肺腺癌。

?

适用疾病: Ovarian Cancer；Non-small Cell Lung Cancer；Platinum-Resistant Ovarian Cancer
干预: TUB-040
地点: United States，Belgium，Germany，Romania 等 3 个
申办方: Tubulis GmbH

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06315491 / NCI-2024-08219

A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer

AI 简述一项II期试验，研究CBX-12用于铂耐药或难治性卵巢癌，在美国开展。

?

适用疾病: Platinum-resistant Ovarian Cancer；Refractory Ovarian Carcinoma；Refractory Primary Peritoneal Serous Adenocarcinoma
干预: CBX-12
地点: United States
申办方: Cybrexa Therapeutics

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06395519

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

AI 简述这是一项I/II期试验，研究PARG抑制剂ETX-19477用于晚期实体恶性肿瘤。在美国开展。

?

适用疾病: Advanced or Metastatic Solid Tumors；Breast Cancer；Ovarian Cancer
干预: ETX-19477
地点: United States
申办方: 858 Therapeutics, Inc.

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT06618235

Trial of THEO-260 in Ovarian Cancer Patients

AI 简述这是一项I/II期试验，研究THEO-260用于卵巢癌，在西班牙和英国开展。

?

适用疾病: Ovarian Cancer
干预: THEO-260
地点: Spain，United Kingdom
申办方: Theolytics Limited

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06639074 / NCI-2024-08466

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

AI 简述这是一项II期试验，研究叶酸受体α树突状细胞用于III/IV期卵巢癌、输卵管癌或原发性腹膜癌。

?

适用疾病: Advanced Fallopian Tube Carcinoma；Advanced Fallopian Tube High Grade Serous Adenocarcinoma；Advanced Ovarian Carcinoma
干预: Biopsy，Biospecimen Collection，Computed Tomography，Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed
地点: United States
申办方: Mayo Clinic

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06682988 / NCI-2026-04199

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

AI 简述这是一项II期试验，研究Mirvetuximab Soravtansine用于铂耐药、FRα高表达的晚期卵巢癌、腹膜癌或输卵管癌。在美国、澳大利亚等地开展。

?

适用疾病: Advanced High-Grade Epithelial Ovarian Cancer；Primary Peritoneal Cancer；Fallopian Tube Cancers
干预: Mirvetuximab Soravtansine
地点: United States，Australia，Belgium，France 等 4 个
申办方: AbbVie

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06690775 / NCI-2024-10013

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

AI 简述这是一项II期试验，研究TORL-1-23用于铂耐药卵巢癌，在美国、澳大利亚等地开展。

?

适用疾病: Epithelial Ovarian Cancer；Primary Peritoneal；Fallopian Tube Cancer
干预: TORL-1-23，Pegfilgrastim (drug)
地点: United States，Australia，Austria，Belgium 等 8 个
申办方: TORL Biotherapeutics, LLC

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov NCT06710288

A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer

AI 简述这是一项II期试验，研究自体M-CENK细胞治疗联合N-803及吉西他滨用于铂耐药复发高级别卵巢癌。在美国开展。

?

适用疾病: Platinum-resistant Ovarian Cancer
干预: Gemcitabine，N-803，M-CENK
地点: United States
申办方: ImmunityBio, Inc.

正在招募 Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT06730347 / NCI-2025-02422

A Study of Lorigerlimab in Participants With Advanced Solid Tumors

AI 简述这是一项II期试验，研究Lorigerlimab用于铂耐药卵巢癌、输卵管癌或原发性腹膜癌。

?

适用疾病: Platinum-resistant Ovarian Cancer；Platinum-Resistant Fallopian Tube Carcinoma；Platinum-Resistant Primary Peritoneal Carcinoma
干预: Lorigerlimab
地点: United States，Canada，South Korea
申办方: MacroGenics

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06787612 / NCI-2025-07201

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

AI 简述这是一项II期试验，研究Ubamatamab联合治疗用于铂耐药卵巢癌，在美国、加拿大、韩国、台湾等地开展。

?

适用疾病: Ovarian Cancer；Fallopian Tube Cancer；Primary Peritoneal Cancer
干预: Ubamatamab，Bevacizumab，Cemiplimab，Fianlimab
地点: United States，Canada，South Korea，Taiwan 等 1 个
申办方: Regeneron Pharmaceuticals

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06815497

Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer

AI 简述这是一项II期试验，研究Telmisartan联合化疗用于铂耐药卵巢癌，在美国开展。

?

适用疾病: Ovarian Cancer
干预: Telmisartan
地点: United States
申办方: Tyler J Curiel

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT06843447 / NCI-2025-05813

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

AI 简述这是一项I/II期试验，研究Raludotatug Deruxtecan用于复发性卵巢癌，在美国、以色列、西班牙和英国等地开展。

?

适用疾病: Ovarian Cancer Recurrent；Recurrent Fallopian Tube Cancer；Recurrent Primary Peritoneal Cancer
干预: Raludotatug Deruxtecan，Carboplatin，Paclitaxel，Bevacizumab
地点: United States，Israel，Spain，United Kingdom
申办方: Merck Sharp & Dohme LLC

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06906341 / NCI-2025-02782

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

AI 简述这是一项II期试验，研究Relacorilant联合不同方案用于妇科癌症，在美国、比利时等地开展。

?

适用疾病: Ovarian Cancer；Fallopian Tube Cancer；Peritoneal Neoplasms
干预: Relacorilant 150 mg once daily (QD)，Nab-paclitaxel 80 mg/m^2，Bevacizumab 10 mg/kg
地点: United States，Belgium，France，Germany 等 4 个
申办方: Corcept Therapeutics

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06971744 / NCI-2026-00102

Autophagy Maintenance (AUTOMAIN)

AI 简述这是一项II期试验，在美国开展，研究羟氯喹、奈非那韦联合贝伐珠单抗用于铂敏感复发性高级别浆液性卵巢癌、输卵管癌或原发性腹膜癌。

?

适用疾病: Ovarian Cancer；Recurrent High Grade Ovarian Serous Adenocarcinoma；Recurrent High Grade Fallopian Tube Serous Adenocarcinoma
干预: Hydroxychloroquine，Nelfinavir，Bevacizumab
地点: United States
申办方: Medical University of South Carolina

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07023627 / NCI-2025-07629

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

AI 简述这是一项II期试验，研究INCB123667用于铂耐药卵巢癌伴Cyclin E1过表达，在美国等地开展。

?

适用疾病: Ovarian Cancer；Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma；Platinum-Resistant Fallopian Tube High Grade Serous Adenocarcinoma
干预: INCB123667
地点: United States，Australia，Belgium，Japan 等 4 个
申办方: Incyte Corporation

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07024784

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

AI 简述这是一项II期试验，研究IMGN151单药或联合卡铂、贝伐珠单抗、奥拉帕利用于妇科癌症，在美国等地开展。

?

适用疾病: Gynecologic Cancers；Platinum-Sensitive Ovarian Cancer；Fallopian Tube Cancer
干预: IMGN151，Carboplatin，Bevacizumab，Olaparib
地点: United States，Israel，Japan
申办方: AbbVie

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07115043 / NCI-2025-09704

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究AZD6750联合rilvegostomig用于多种晚期实体瘤。在美国、澳大利亚、日本、韩国等地开展。

?

适用疾病: Melanoma；Non-small Cell Lung Cancer；Squamous Cell Carcinoma (Skin)
干预: AZD6750，rilvegostomig
地点: United States，Australia，Japan，South Korea
申办方: AstraZeneca

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07265739

Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer

AI 简述这是一项II期试验，在美国开展，研究氯沙坦联合紫杉醇用于铂耐药卵巢癌。

?

适用疾病: Platinum Resistant Ovarian Cancer
干预: losartan，Paclitaxel
地点: United States
申办方: Massachusetts General Hospital

正在招募 Phase 1

NCI NCT04693468 / NCI-2020-06041

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

AI 简述这是一项I期试验，研究Talazoparib联合Palbociclib、Axitinib或Crizotinib用于晚期或转移性实体瘤，在美国开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1

NCI NCT04516447 / NCI-2020-07262

A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

AI 简述这是一项I期试验，研究Azenosertib用于卵巢癌。

?

适用疾病: High Grade Ovarian Serous Adenocarcinoma；Primary Peritoneal High Grade Serous Adenocarcinoma；High Grade Fallopian Tube Serous Adenocarcinoma
干预: 未列出
地点: United States
申办方: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

正在招募 Phase 1

NCI NCT04890613 / NCI-2021-09946

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

AI 简述这是一项I期试验，研究CX-5461用于携带BRCA1/2、PALB2或同源重组修复缺陷突变的实体瘤。

?

适用疾病: High Grade Ovarian Serous Adenocarcinoma；Primary Peritoneal High Grade Serous Adenocarcinoma；High Grade Fallopian Tube Serous Adenocarcinoma
干预: 未列出
地点: United States
申办方: Senhwa Biosciences, Inc.

正在招募 Phase 1

NCI NCT05227326 / NCI-2021-14102

AOH1996 for the Treatment of Refractory Solid Tumors

AI 简述这是一项I期试验，研究AOH1996用于多种难治性实体瘤。

?

适用疾病: Refractory Malignant Solid Tumor；Refractory Pancreatic Carcinoma；Refractory Osteosarcoma
干预: 未列出
地点: United States
申办方: City of Hope Comprehensive Cancer Center

正在招募 Phase 1

NCI NCT05316129 / NCI-2022-03105

Genetically Engineered Cells (FSHCER T cells) for the Treatment of Recurrent Platinum-resistant or Platinum-refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

AI 简述这是一项1期试验，在美国研究基因工程T细胞用于复发铂耐药卵巢癌、原发性腹膜癌或输卵管癌。

?

适用疾病: Recurrent Ovarian Endometrioid Adenocarcinoma；Refractory Ovarian Endometrioid Adenocarcinoma；Recurrent Fallopian Tube Serous Adenocarcinoma
干预: 未列出
地点: United States
申办方: Moffitt Cancer Center

正在招募 Phase 1

NCI NCT05107674 / NCI-2023-00784

A Study of NX-1607 in Adults With Advanced Malignancies

AI 简述这是一项I期试验，研究NX-1607用于晚期恶性肿瘤。

?

适用疾病: Metastatic Urothelial Cancer；Intermediate Atypical Prostate Carcinoma；Platinum-Resistant Ovarian Cancer
干预: 未列出
地点: United States
申办方: Nurix Inc

正在招募 Phase 1

NCI NCT05932862 / NCI-2023-10500

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究XL309单药或联合治疗用于晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Stage II Pancreatic Cancer
干预: 未列出
地点: United States
申办方: Exelixis Inc

正在招募 Phase 1

NCI NCT06040970 / NCI-2024-02787

Sacituzumab Govitecan in Combination with Cisplatin for the Treatment of Patients with Recurrent Platinum-sensitive Ovarian or Endometrial Cancer

AI 简述这是一项I期试验，研究Sacituzumab Govitecan联合顺铂用于复发性铂敏感卵巢癌或子宫内膜癌。

?

适用疾病: Recurrent Platinum-Sensitive Ovarian Carcinoma；Recurrent Platinum-Sensitive Fallopian Tube Carcinoma；Recurrent Platinum-Sensitive Primary Peritoneal Carcinoma
干预: 未列出
地点: United States
申办方: Icahn School of Medicine at Mount Sinai

正在招募 Phase 1

NCI NCT06431594 / NCI-2024-08554

A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)

AI 简述这是一项I期试验，研究Mocertatug Rezetecan用于晚期实体瘤，包括子宫内膜癌、卵巢癌，在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Uterine (including Endometrial) Cancer；Stage IV Uterine (including Endometrial) Cancer
干预: 未列出
地点: United States
申办方: GlaxoSmithKline

正在招募 Phase 1

NCI NCT06792552 / NCI-2025-06352

A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究SIM0505用于晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Lung Cancer；Stage IV Lung Cancer
干预: 未列出
地点: United States
申办方: NextCure, Inc.

正在招募 Phase 1

NCI NCT06930755 / NCI-2025-08593

Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer

AI 简述这是一项I期试验，研究NMS-03305293用于复发高级别卵巢浆液性腺癌，在美国开展。

?

适用疾病: Recurrent High Grade Ovarian Serous Adenocarcinoma；Recurrent High Grade Fallopian Tube Serous Adenocarcinoma；Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma
干预: 未列出
地点: United States
申办方: Nerviano Medical Sciences

正在招募 Phase 1

NCI NCT07213791 / NCI-2025-09175

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

AI 简述这是一项I期试验，在美国等地研究LY4337713用于FAP阳性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Eli Lilly and Company

正在招募 Phase 1

NCI NCT06809114 / NCI-2026-00164

FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors

AI 简述这是一项I期试验，研究AT03-65用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Axcynsis Therapeutics Pte Ltd

正在招募 Phase 1

NCI NCT07541573 / NCI-2026-03508

A Camelid Nanobody B7-H3 Tri-Specific Killer Engager (GTB-5550) for the Treatment of Advanced Solid Tumors that Failed Prior Therapy

AI 简述这是一项I期试验，研究GTB-5550用于既往治疗失败的晚期实体瘤，在美国开展。

?

适用疾病: Recurrent Fallopian Tube Cancer；Recurrent Primary Peritoneal Cancer；Recurrent Bladder Urothelial Cancer
干预: 未列出
地点: United States
申办方: University of Minnesota/Masonic Cancer Center

正在招募 Phase 1

NCI NCT07278336 / NCI-2026-03775

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer

AI 简述这是一项1期试验，研究ABBV901单药或联合贝伐珠单抗用于卵巢癌、输卵管癌或腹膜癌。在美国开展。

?

适用疾病: Stage III Ovarian Cancer；Stage IV Ovarian Cancer；Stage III Fallopian Tube Cancer
干预: 未列出
地点: United States
申办方: Abbvie

正在招募 Phase 1 药物

ClinicalTrials.gov NCT04389632

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

AI 简述这是一项I期试验，研究Sigvotatug Vedotin用于晚期实体瘤，在美国、法国、韩国、西班牙等地开展。

?

适用疾病: Carcinoma, Non-Small Cell Lung；Squamous Cell Carcinoma of Head and Neck；HER2 Negative Breast Neoplasms
干预: sigvotatug vedotin，pembrolizumab，cisplatin，carboplatin
地点: United States，France，South Korea，Spain 等 3 个
申办方: Seagen, a wholly owned subsidiary of Pfizer

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT04585958 / NCI-2020-07841

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

AI 简述这是一项I期试验，研究DS-8201a联合奥拉帕利用于HER2表达肿瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Neoplasm；Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma；Unresectable Malignant Solid Neoplasm
干预: Biopsy Procedure，Biospecimen Collection，Computed Tomography，Echocardiography Test
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1 药物手术/操作

ClinicalTrials.gov / NCI NCT04633239 / NCI-2020-10084

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

AI 简述这是一项I期试验，研究Abemaciclib联合Olaparib用于复发性卵巢癌，在美国开展。

?

适用疾病: Recurrent Ovarian High Grade Serous Adenocarcinoma；Recurrent Platinum-Resistant Ovarian Carcinoma；Recurrent High Grade Ovarian Serous Adenocarcinoma
干预: Abemaciclib，Biopsy Procedure，Biospecimen Collection，Olaparib
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05005403 / NCI-2025-01100

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

AI 简述这是一项I期试验，研究Azirkitug单药或联合其他药物用于非小细胞肺癌等实体瘤，在美国、加拿大等地开展。

?

适用疾病: Non-Small Cell Lung Cancer；Head and Neck Squamous Cell Carcinoma；Micro Satellite Stable Colorectal Cancer
干预: Azirkitug，Budigalimab，Bevacizumab，Telisotuzumab Adizutecan
地点: United States，Canada，Israel，Japan 等 2 个
申办方: AbbVie

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT05039801 / NCI-2021-09063

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

AI 简述这是一项I期试验，研究IACS-6274联合或不联合Bevacizumab和Paclitaxel用于晚期实体瘤。

?

适用疾病: Advanced Endometrial Carcinoma；Advanced Head and Neck Squamous Cell Carcinoma；Advanced Malignant Solid Neoplasm
干预: Bevacizumab，Glutaminase-1 Inhibitor IACS-6274，Paclitaxel，Capivasertib
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT05225363 / NCI-2021-10838

Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer

AI 简述这是一项I期试验，在美国研究TAG72-CAR T细胞用于铂耐药上皮性卵巢癌。

?

适用疾病: Platinum-Resistant Ovarian Carcinoma；Platinum-Resistant Ovarian Cancer
干预: Chimeric Antigen Receptor T-cells，Cyclophosphamide，Fludarabine
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05636111 / NCI-2022-10037

Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

AI 简述这是一项I期试验，研究Lurbinectedin联合Paclitaxel和Bevacizumab用于铂耐药卵巢癌。

?

适用疾病: Ovarian Cancer；Platinum-Resistant Ovarian Cancer；Platinum-Resistant Fallopian Tube Cancer
干预: Paclitaxel，Bevacizumab，Lurbinectedin
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1 药物手术/操作

ClinicalTrials.gov / NCI NCT05950464 / NCI-2023-03408

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

AI 简述这是一项1期试验，研究M1774联合ZEN-3694用于复发性卵巢癌和子宫内膜癌，在美国开展。

?

适用疾病: Recurrent Endometrial Carcinoma；Recurrent Endometrial Clear Cell Adenocarcinoma；Recurrent Endometrial Endometrioid Adenocarcinoma
干预: BET Bromodomain Inhibitor ZEN-3694，Biopsy Procedure，Biospecimen Collection，Computed Tomography
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06234423 / NCI-2024-03871

A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

AI 简述这是一项1期试验，研究CUSP06用于铂类难治/耐药卵巢癌及其他晚期实体瘤。

?

适用疾病: Ovarian Cancer；Solid Tumor；Advanced Malignant Solid Tumor
干预: CUSP06
地点: United States，Australia
申办方: OnCusp Therapeutics, Inc.

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT06242470

A Study of MGC026 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究MGC026用于晚期实体瘤患者，在美国、澳大利亚、英国等地开展。

?

适用疾病: Advanced Solid Tumor；Advanced Cancer；Metastatic Cancer
干预: MGC026 Dose Escalation，MGC026 Dose for Expansion
地点: United States，Australia，United Kingdom
申办方: MacroGenics

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT06305299 / NCI-2024-02577

Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

AI 简述这是一项I期试验，研究靶向B7H3的CAR-T细胞用于复发性卵巢癌。

?

适用疾病: Ovary Neoplasm；Ovarian Cancer；Epithelial Ovarian Cancer
干预: iC9-CAR.B7-H3 T cells，Cyclophosphamide，Fludarabine
地点: United States
申办方: UNC Lineberger Comprehensive Cancer Center

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT06321484 / NCI-2024-08624

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

AI 简述这是一项I期试验，研究细胞因子诱导的记忆样自然杀伤细胞用于铂耐药复发性卵巢癌，在美国开展。

?

适用疾病: Platinum-resistant Ovarian Cancer；Recurrent Ovary Cancer；Ovarian Cancer
干预: Cytokine-Induced Memory-like Natural Killer Cells，Interleukin 2
地点: United States
申办方: Dana-Farber Cancer Institute

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT06404671

Timing of Surgery After Neoadjuvant Chemotherapy for Advanced Ovarian Cancer

AI 简述这是一项观察性试验，比较延迟与早期间歇性减瘤术用于晚期卵巢癌患者，在埃及开展。

?

适用疾病: Ovarian Epithelial Cancer
干预: Delayed interval cytoreductive surgery (DICS)，Early interval cytoreductive surgery (EICS)
地点: Egypt
申办方: Alexandria University

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06458712

Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

AI 简述这是一项I期试验，在美国、法国等地研究DSB2455用于晚期实体瘤。

?

适用疾病: Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Metastases)
干预: DSB2455
地点: United States，France，Hungary，Spain
申办方: Duke Street Bio Ltd

正在招募阶段未标明药物其他

ClinicalTrials.gov NCT06466382

OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy

AI 简述这是一项在瑞士开展的试验，研究基于分子肿瘤委员会的个体化治疗用于卵巢上皮癌、输卵管癌等。

?

适用疾病: Ovarian Neoplasm Epithelial；Fallopian Tube Neoplasms；Ovarian Endometrioid Carcinoma
干预: Treatment recommendation by molecular tumorboard (mTB) based on tumor profiling，Carboplatin / Paclitaxel Chemotherapy
地点: Switzerland
申办方: Swiss GO Trial Group

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06476808

A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

AI 简述这是一项I期试验，研究BMS-986463用于晚期恶性实体瘤，在美加法等国开展。

?

适用疾病: High-grade Serous Ovarian Carcinoma (HGSOC)；Uterine Serous Carcinoma (USC)；Non-small Cell Lung Cancer (NSCLC)
干预: BMS-986463
地点: United States，Canada，France，Italy 等 1 个
申办方: Bristol-Myers Squibb

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06483048 / NCI-2024-05158

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

AI 简述这是一项I期试验，研究自体MUC1激活T细胞用于复发耐药卵巢癌，在美国开展。

?

适用疾病: Platinum-Resistant Fallopian Tube Carcinoma；Platinum-Resistant Ovarian Carcinoma；Platinum-Resistant Primary Peritoneal Carcinoma
干预: Autologous MUC1-activated T-cells，Bendamustine，Biospecimen Collection，Computed Tomography
地点: United States
申办方: Mayo Clinic

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06513624

ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers

AI 简述这是一项I期试验，研究ETC-159联合帕博利珠单抗用于MSS/pMMR晚期铂耐药卵巢癌，在新加坡开展。

?

适用疾病: With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer
干预: ETC-159，Pembrolizumab，Denosumab / Zoledronic Acid
地点: Singapore
申办方: National University Hospital, Singapore

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06515613 / NCI-2024-09511

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

AI 简述这是一项I期试验，研究CTIM-76用于铂耐药卵巢癌及其他晚期实体瘤。在美国、英国开展。

?

适用疾病: Platinum-resistant Ovarian Cancer；Testicular Cancer；Endometrial Cancer
干预: CTIM-76
地点: United States，United Kingdom
申办方: Context Therapeutics Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06547840

A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha

AI 简述这是一项I期试验，研究MOv18 IgE用于表达叶酸受体α的实体瘤。在英国等地开展。

?

适用疾病: Advanced Ovarian Cancer；Platinum-resistant Ovarian Cancer；Triple Negative Breast Cancer (TNBC)
干预: MOv18 IgE
地点: United Kingdom
申办方: Epsilogen Ltd

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06586957 / NCI-2025-00731

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

AI 简述这是一项I期试验，研究NKT3964用于晚期/转移性实体瘤。在美国开展。

?

适用疾病: Solid Tumor；Advanced Solid Tumor；Solid Tumor, Adult
干预: NKT3964
地点: United States
申办方: NiKang Therapeutics, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06646627 / NCI-2025-00266

Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors

AI 简述这是一项I期试验，研究自体B7-H3 CAR-T细胞用于复发铂耐药卵巢肿瘤。

?

适用疾病: Ovarian Cancer；Recurrent Platinum-Resistant Ovarian Carcinoma；Platinum-Refractory Ovarian Carcinoma
干预: B7-H3CART
地点: United States
申办方: Stanford University

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06799065 / NCI-2025-03601

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

AI 简述这是一项I期试验，研究ATX-295用于晚期或转移性实体瘤。

?

适用疾病: Advanced Solid Tumors；Breast Cancer Recurrent；Ovarian Cancer
干预: ATX-295
地点: United States
申办方: Accent Therapeutics

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06856499 / NCI-2024-09126

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

AI 简述这是一项I期试验，研究Cirtuvivint联合奥拉帕利用于BRCA/HRD突变铂耐药卵巢癌。

?

适用疾病: Endometrioid Ovarian Cancer；Primary Peritoneal Cancer；Fallopian Tube Cancer
干预: Cirtuvivint，Olaparib
地点: United States
申办方: University of Colorado, Denver

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06964009 / NCI-2025-04856

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

AI 简述这是一项I期试验，在美国研究DT2216联合紫杉醇用于铂耐药卵巢癌。

?

适用疾病: Ovarian Cancer；Ovarian Carcinoma；Recurrent Ovary Cancer
干预: DT2216，Paclitaxel
地点: United States
申办方: Elizabeth Stover, MD, PhD

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06976892

Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer

AI 简述这是一项I期试验，研究Idetrexed联合Olaparib用于高级别浆液性卵巢癌。

?

适用疾病: High Grade Serous Ovarian Cancer
干预: Dose Level 2 (starting dose)，Dose Level 1，Dose Level -1，Dose Level 3
地点: United Kingdom
申办方: Institute of Cancer Research, United Kingdom

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT07030907 / NCI-2025-04629

A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer

AI 简述这是一项1期试验，研究OPB-101用于铂耐药卵巢癌。

?

适用疾病: Ovarian Cancer Recurrent；Ovarian Cancer；Platinum Resistant Ovarian Cancer
干预: OPB-101
地点: United States
申办方: Outpace Bio, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07069335

A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer

AI 简述这是一项I期试验，研究Olaparib用于BRCA突变晚期卵巢癌。

?

适用疾病: Ovarian Cancer
干预: Olaparib 150 MG
地点: South Korea
申办方: Boryung Pharmaceutical Co., Ltd

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT07211659 / NCI-2025-07658

Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients

AI 简述这是一项I期试验，研究THEO-260经腹腔给药用于卵巢癌。在美国开展。

?

适用疾病: Ovarian Cancer；Stage III Ovarian Cancer；Stage IV Ovarian Cancer
干预: THEO-260
地点: United States
申办方: Theolytics Limited

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07226427 / NCI-2026-00272

A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer

AI 简述这是一项I期试验，研究MEN2501用于铂耐药卵巢癌，在美国、澳大利亚、西班牙等地开展。

?

适用疾病: Platinum-resistant Ovarian Cancer；Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma；Platinum-Resistant Fallopian Tube High Grade Serous Adenocarcinoma
干预: MEN2501
地点: United States，Australia，Spain
申办方: Stemline Therapeutics, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07371104

Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer

AI 简述这是一项I期试验，研究DWZ2501用于BRCA突变高级别卵巢癌，在韩国开展。

?

适用疾病: Cancer；Ovarian Cancer
干预: DWZ2501 (Olaparib 150mg)，DWC202510 (Olaparib 150mg)
地点: South Korea
申办方: Daewoong Pharmaceutical Co. LTD.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07444814 / NCI-2026-01993

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究HWK-007用于晚期实体瘤。

?

适用疾病: Endometrial Cancer；Ovarian Cancer；Ovarian Cancer Metastatic
干预: HWK-007
地点: United States
申办方: Whitehawk Therapeutics, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07470853

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

AI 简述这是一项I期试验，研究MUC16靶向ADC HWK-016用于晚期实体瘤。

?

适用疾病: PROC；Platinum Resistant Ovarian Cancer；Endometrial Cancer
干预: HWK-016, MUCIN-16-targeted ADC，Bevacizumab
地点: United States
申办方: Whitehawk Therapeutics, Inc.

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT07489287 / NCI-2026-01818

GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer

AI 简述这是一项I期试验，研究GB-5267用于铂耐药卵巢癌、腹膜癌或输卵管癌，在美国开展。

?

适用疾病: Platinum-resistant Ovarian Cancer；Platinum-Resistant Ovarian Cancer；Platinum-Resistant Fallopian Tube Cancer
干预: GB-5267 - IV only，GB-5267 -Combined IV and IP Infusion
地点: United States
申办方: Roswell Park Cancer Institute

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07503808 / NCI-2026-03006

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

AI 简述这是一项I期试验，研究IDE034用于局部晚期或转移性实体瘤成人患者。

?

适用疾病: Esophageal Squamous Cell Carcinoma；High Grade Serous Ovarian Cancer；Head and Neck Squamous Cell Carcinoma
干预: IDE034
地点: United States
申办方: IDEAYA Biosciences

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT07665515

Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

AI 简述这是一项I期试验，研究CryptiVax-1001用于晚期浆液性卵巢癌、输卵管癌或原发性腹膜癌的维持治疗。

?

适用疾病: Ovarian Cancer；HGSOC；HGS Ovarian, Fallopian Tube or Primary Peritoneal Cancer
干预: CryptiVax-1001
地点: United Kingdom
申办方: Epitopea Ltd

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07690189

Phase 1 Study of NTB-928 in R/R OC

AI 简述这是一项I期试验，研究NTB-928用于复发/难治性卵巢癌。在美国等地开展。

?

适用疾病: Relapsed/Refractory Ovarian Carcinoma
干预: NTB-928
地点: United States
申办方: TeneoSeven, Inc.

即将招募 Phase 3 药物

ClinicalTrials.gov NCT06867562

Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer

AI 简述这是一项III期试验，比较紫杉醇脂质混悬液与常规紫杉醇用于铂耐药卵巢癌。

?

适用疾病: Platinum-Resistant Primary Peritoneal Carcinoma；Platinum Resistant High Grade Epithelial Ovarian Cancer；Platinum Resistant High Grade Serous Ovarian Cancer
干预: Paclitaxel Lipid Suspension，Conventional paclitaxel or Taxol
地点: 未列出
申办方: Jina Pharmaceuticals Inc.

暂时不招募 O

NCI NCT02659241 / NCI-2016-00118

Adavosertib before Surgery in Treating Patients with Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

AI 简述这是一项0期试验，研究Adavosertib用于晚期高级别卵巢癌、输卵管癌或原发性腹膜癌。

?

适用疾病: High Grade Ovarian Serous Adenocarcinoma；Stage III Primary Peritoneal Cancer；Stage IIIA Primary Peritoneal Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募 O

NCI NCT03943173 / NCI-2019-00503

Olaparib in Treating Patients with Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer before Surgery

AI 简述这是一项其他类型试验，研究奥拉帕利用于新诊断BRCA突变卵巢癌、原发性腹膜癌或输卵管癌术前治疗，在美国开展。

?

适用疾病: High Grade Ovarian Serous Adenocarcinoma；Primary Peritoneal High Grade Serous Adenocarcinoma；High Grade Fallopian Tube Serous Adenocarcinoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募 Phase 1

NCI NCT04840589 / NCI-2021-02850

Testing the Combination of ZEN003694 and Nivolumab with or without Ipilimumab in Solid Tumors

AI 简述这是一项I期试验，研究ZEN003694联合Nivolumab和Ipilimumab用于复发转移实体瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Refractory Ovarian Carcinoma
干预: 未列出
地点: United States
申办方: UPMC Hillman Cancer Center LAO

暂时不招募 Phase 1, Phase 2

NCI NCT05922930 / NCI-2023-05027

Intraperitoneal TROP2-CAR-NK for the Treatment of Patients with Platinum-Resistant High Grade Ovarian Cancer, Mesonephric-Like Adenocarcinoma and Pancreatic Cancer

AI 简述这是一项I/II期试验，在美国研究腹腔内TROP2-CAR-NK治疗铂耐药卵巢癌、中肾管样腺癌和胰腺癌。

?

适用疾病: High Grade Ovarian Serous Adenocarcinoma；Primary Peritoneal High Grade Serous Adenocarcinoma；High Grade Fallopian Tube Serous Adenocarcinoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06650709

NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study

AI 简述这是一项II期试验，研究奥拉帕利联合贝伐珠单抗和Durvalumab用于IV期卵巢癌的新辅助治疗。

?

适用疾病: Ovarian Cancer Stage IV
干预: Olaparib，Bevacizumab，Durvalumab
地点: 未列出
申办方: British Columbia Cancer Agency

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07273396

Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer

AI 简述这是一项I/II期试验，研究加压腹腔内气溶胶化疗（PIPAC）使用紫杉醇用于铂耐药复发性卵巢癌。

?

适用疾病: Ovarian Neoplasms；Peritoneal Neoplasms
干预: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) using paclitaxel
地点: 未列出
申办方: Seoul National University Hospital

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07462468

A Phase 1 Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer.

AI 简述这是一项I期试验，研究WSK-IM02用于铂耐药复发性卵巢癌。

?

适用疾病: Platinum-resistant Recurrent Ovarian Cancer (PROC)
干预: WSK-IM02，WSK-IM02
地点: 未列出
申办方: WestVac Biopharma Co., Ltd.

即将招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov NCT07504588

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

AI 简述这是一项II期试验，比较Sacituzumab Govitecan联合Bevacizumab与化疗用于复发性铂敏感卵巢癌。

?

适用疾病: Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma；Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma；Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma
干预: Anti-VEGF Monoclonal Antibody，Bevacizumab，Biospecimen Collection，Carboplatin
地点: 未列出
申办方: National Cancer Institute (NCI)

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07532148

Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

AI 简述这是一项I期试验，研究CKD-215和D215用于BRCA突变晚期卵巢癌。

?

适用疾病: Ovarian Cancer
干预: CKD-215，D215
地点: 未列出
申办方: Chong Kun Dang Pharmaceutical

即将招募 Phase 1 生物制剂

ClinicalTrials.gov NCT07664735

A Phase 1 Study to Evaluate the Safety and Efficacy of OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.

AI 简述这是一项I期试验，研究OPB-201用于复发性子宫内膜癌和铂耐药卵巢癌。

?

适用疾病: Endometrial Cancer Recurrent；Endometrial Cancer；Advanced Endometrial Cancer
干预: OPB-201
地点: 未列出
申办方: Outpace Bio, Inc.

术语	中文意思	对找临床试验有什么用
高级别浆液性卵巢癌 / High-grade serous	卵巢癌中常见且研究较多的病理类型。	很多试验会限定 high-grade serous 或 epithelial ovarian cancer。
BRCA mutation	BRCA1/2 突变可能与 DNA 修复相关。	可以找 PARP 抑制剂、DNA damage repair 相关试验。
HRD	同源重组修复缺陷，是一类 DNA 修复相关状态。	PARP 或联合治疗试验可能要求 HRD 状态。
Platinum-sensitive	通常指含铂治疗后较长时间才复发，具体定义看试验。	很多复发卵巢癌试验会按铂敏感分组。
Platinum-resistant	通常指含铂治疗后较短时间内进展或复发。	铂耐药卵巢癌有专门试验方向，如 ADC、免疫或靶向联合。

Recruiting	正在招募，可能仍可申请参加。
Not yet recruiting	尚未开始招募，可关注后续开放时间。
Active, not recruiting	试验仍在进行，但通常不再招新患者。
Completed	试验已经完成。
Terminated	试验提前终止。
Unknown	公开页面上的状态不明确或未及时更新。

卵巢癌

当前同步到的治疗类试验

建议拆分方向

英文搜索关键词

这些关键词怎么理解